

RECEIVED
CENTRAL FAX CENTER
OCT 08 2004

PATENT
Docket No. 275.00030103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Li et al.)	Group Art Unit:	1645
)		
Serial No.:	10/772,661)	Examiner:	Unassigned
Confirmation No.:	5608)		
)		
Filed:	February 5, 2004)		
)		
For:	COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION OF GENE EXPRESSION USING DOUBLE STRANDED RNA			

FACSIMILE TRANSMISSION TO THE PTO

Mail Stop Amendment	
Commissioner for Patents	FAX NUMBER: <u>(703) 872-9306</u>
P.O. Box 1450	Total Pages (including cover page): <u>5</u>
Alexandria, VA 22313-1450	Time: <u>2:00pm</u> (Central Time)
(Transmission must be complete by midnight eastern time.)	

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission: SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (2 PGS); 1449 FORM (2 PGS.)

Small Entity Status is entitled to be asserted in the above-identified application.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Mueeting, Raasch & Gebhardt, P.A.
Customer Number: 26813

October 8, 2004
Date

By: David L. Provence
David L. Provence
Reg. No. 43,022
Direct Dial (612)305-1005

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on this 8 day of OCTOBER, 2004, at 2:00 pm (Central Time).

10-8-04
Date

Signature: Sandy Truehart
Name: Sandy Truehart

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

RECEIVED
CENTRAL FAX CENTER

OCT 08 2004

PATENT
Docket No. 275.00030103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Li et al.)	Group Art Unit:	1645
)		
Serial No.:	10/772,661)	Examiner:	Unassigned
Confirmation No.:	5608)		
)		
Filed:	February 5, 2004)		
)		
For:	COMPOSITION AND METHOD FOR IN VIVO AND IN VITRO ATTENUATION OF GENE EXPRESSION USING DOUBLE STRANDED RNA			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials noted herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested.

As this patent application was filed after June 30, 2003, copies of the U.S. patents and U.S. patent application publications listed on the attached 1449 form(s) have not been submitted. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Supplemental Information Disclosure Statement
 Serial No. 10/722,661
 Filed: February 5, 2004

Page 2 of 2

This application is a continuation of U.S. Patent Application Serial No. 10/038,984, filed January 4, 2002. In accordance with 37 C.F.R. §1.98(d), copies of documents previously cited by or submitted to the U.S. Patent and Trademark Office in connection with Applicants' prior application(s) listed above, are not included herewith.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

<p>CERTIFICATE UNDER 37 C.F.R. 1.8:</p> <p>The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>8</u> day of <u>OCTOBER</u> 2004, at <u>2:00 pm</u> (Central Time).</p> <p><u>Sandy Truehart</u> Name: <u>Sandy Truehart</u></p>

October 8, 2004
 Date

DLP/sjt

Respectfully submitted for
 LI et al.
 By
 Mueeting, Raasch & Gebhardt, P.A.
 P.O. Box 581415
 Minneapolis, MN 55458-1415
 Phone: (612)305-1220
 Facsimile: (612)305-1228
 Customer Number 26813

By: David L. Provence
 David L. Provence
 Reg. No. 43,022
 Direct Dial (612)305-1005

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 275.00030103	Serial No.: 10/772,661
	Applicant(s): Li et al.	Confirmation No.: 5608
	Application Filing Date: 02/05/04	Group: 1645
	Information Disclosure Statement mailed:	October 8, 2004

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		6,506,559	01-2003	Fire et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		NONE						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
		Agami, "RNAi and related mechanisms and their potential use for therapy," <i>Current Opinion in Chemical Biology</i> , 2002, Vol. 6:829-834
		Agrawal et al., "Antisense Therapeutics: is it as simple as complementary base recognition?," <i>Molecular Medicine Today</i> , 2000, Vol. 6:72-81
		Caplen, "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> 2003, Vol. 3:575-586
		Check, "RNA to the rescue?," <i>Nature</i> , 2003, Vol. 425:10-12
		Coburn et al., "siRNAs: a new wave fo RNA-based therapeutics," <i>Journal of Antimicrobial Chemotherapy</i> 2003, Vol. 51:753-756
		Flanagan et al., "Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide," <i>Nature Biotechnology</i> . 1999, Vol. 17:48-52
		Green et al., "Antisense Oligonucleotides: an evolving technology for the modulation of gene expression in human disease," <i>J. Am. Coll. Surg.</i> 2000, Vol. 191:93-105
		Jen et al., "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> 2000, Vol. 18:307-319
		Opalinska et al. "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Review</i> , 2002, Vol.1:503-514

EXAMINER**Date Considered**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 275.00030103	Serial No.: 10/772,661
	Applicant(s): Li et al.	Confirmation No.: 5608
	Application Filing Date: 02/05/04	Group: 1645
	Information Disclosure Statement mailed: October 8, 2004	

Examiner Initial	Copy Enclosed	Document Description
		Wang et al., "Progress in the Delivery of Therapeutic Oligonucleotides: Organ/Cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo," <i>Antisense and Nucleic Acid Drug Delivery</i> , 2003, Vol.13:169-189
		Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology," <i>Current Pharmaceutical Biotechnology</i> , 2004, Vol.5:1-7

EXAMINER	Date Considered
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	